Notable 52-Week Highs and Lows 8/18: (WMT) (BLDP) (CLR) High; (GEO) (EARS) (VRS) Low

August 18, 2016 3:09 PM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

52-Week High:
  • Wal-mart (NYSE: WMT) $75.19. Wal-mart reported Q2 EPS of $1.07, which was $0.05 better than the analyst estimate of $1.02. Revenue for the quarter came in at $120.9 billion versus the consensus estimate of $120.16 billion. Wal-mart said it now sees FY2017 EPS of $4.15-$4.35, versus prior guidance of $4.00-$4.30 and the consensus of $4.27.

  • Ballard Power Systems (Nasdaq: BLDP) $2.37. Ballard Power Systems announced that it has signed a Distribution Agreement with Toyota Tsusho Corporation ("TTC), a member Company of the Toyota Group. Under the agreement, TTC will act as a distributor of Ballard-powered fuel cell products in Japan. The initial term of the agreement runs to December 31, 2020.

  • Continental (NYSE: CLR) $48.72. Continental announced that it has signed a definitive purchase and sale agreement with an undisclosed buyer to sell non-strategic properties in North Dakota and Montana for $222 million. The sale includes 68,000 net acres of leasehold primarily in western Williams County, North Dakota, and 12,000 net acres of leasehold in Roosevelt County, Montana. The sale also includes net production of approximately 2,800 barrels of oil equivalent (Boe) per day. The agreement provides for customary closing conditions and adjustments.
52-Week Low:
  • GEO Group (NYSE: GEO) $16.26. GEO Group hit following news that the U.S. Dept. of Justic plans to phase-out use of private prisons.

  • Auris Medical Holding AG (Nasdaq: EARS) $1.95. Auris Medical announced top-line results from the Phase 3 TACTT2 trial with Keyzilen (AM-101) in acute inner ear tinnitus. The TACTT2 trial did not meet the two co-primary efficacy endpoints of statistically significant changes in tinnitus loudness and tinnitus burden compared to placebo. Data from the TACTT2 trial support the positive safety profile established in previous studies, and results from the second Phase 3 trial, TACTT3, are expected in the fourth quarter of 2016.

  • Verso Corporation (NYSE: VRS) $5.99. Verso continuing lower from Tuesday after reporting Q2 results. The company said that net sales for the second quarter of 2016 were 19% lower than the second quarter of 2015. Net loss was $33 million, versus $60 million posted in Q215.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Special Reports

Add Your Comment